Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406702 · ClinicalTrials.gov registry record · Phase 2
CX-8998 for Absence Seizures
A Phase 2 study of Epilepsy, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 7
- Study locations
NCT03406702 is a Phase 2 study of Epilepsy that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 7 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT03406702, a Phase 2 study of Epilepsy, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.
Conditions Studied
Interventions
- DRUG CX-8998
Study Locations (7)
Arkansas
- Arkansas Epilepsy Program - Little Rock
Florida
- University of Florida - Tampa
Kentucky
- Bluegrass Epilepsy Research, LLC - Lexington
Massachusetts
- Tufts Medical Center - Boston
New York
- NYU Comprehensive Epilepsy Center - New York
Ohio
- Cincinnati Children's Hospital - Cincinnati
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-02-25 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406702
The ClinicalTrials.gov registry entry for NCT03406702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which CX-8998 is the first listed.
NCT03406702 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arkansas, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT03406702 about?
NCT03406702 is a clinical study titled "CX-8998 for Absence Seizures". This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.
What is the current status of trial NCT03406702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2018-02-25. Estimated completion is 2019-03-29.
What conditions does trial NCT03406702 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT03406702?
The interventions under investigation include: CX-8998 (DRUG).
Who is sponsoring clinical trial NCT03406702?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03406702 being conducted?
This trial has 7 study locations across Arkansas, Florida, Kentucky, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.